{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(1)"],"submitter":["Wimmer K"],"funding":["Austrian Breast &amp; Colorectal Study Group"],"pubmed_abstract":["<h4>Background</h4>Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as PD-1 inhibition. However, the expected stimulatory effect on lymphocytes may depend on the chemotherapy backbone. Therefore, we separately compared the immunomodulatory effects of EC and D in the setting of a randomized clinical trial.<h4>Methods</h4>Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tumor-infiltrating lymphocytes, circulating lymphoc"],"journal":["Journal of experimental & clinical cancer research : CR"],"pagination":["300"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10644559"],"repository":["biostudies-literature"],"pubmed_title":["Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients."],"pmcid":["PMC10644559"],"pubmed_authors":["Birnleitner H","Egle D","Frantal S","Exner R","Fitzal F","Wimmer K","Bago-Horvath Z","Balic M","Oehler R","Rudas M","Filipits M","Brostjan C","Gnant M","Singer CF","Sachet M","Bartsch R","Ramos C"],"additional_accession":[]},"is_claimable":false,"name":"Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.","description":"<h4>Background</h4>Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as PD-1 inhibition. However, the expected stimulatory effect on lymphocytes may depend on the chemotherapy backbone. Therefore, we separately compared the immunomodulatory effects of EC and D in the setting of a randomized clinical trial.<h4>Methods</h4>Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tumor-infiltrating lymphocytes, circulating lymphoc","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2025-04-05T08:50:50.216Z","creation":"2025-02-19T04:23:14.476Z"},"accession":"S-EPMC10644559","cross_references":{"pubmed":["37957750"],"doi":["10.1186/s13046-023-02876-x"]}}